Log In
Print
BCIQ
Print
Print this Print this
 

ALN-AAT

  Manage Alerts
Collapse Summary General Information
Company Alnylam Pharmaceuticals Inc.
DescriptionShort interfering RNA (siRNA) targeting alpha 1-antitrypsin (AAT; A1AT; SERPINA1) conjugated to GalNAc ligand
Molecular Target Alpha 1-antitrypsin (AAT) (A1AT) (SERPINA1)
Mechanism of ActionGene silencing
Therapeutic ModalityNucleic acid: Linear RNA: siRNA
Latest Stage of DevelopmentPreclinical
Standard IndicationLiver disease
Indication DetailsTreat liver disease caused by alpha 1-antitrypsin (AAT; A1AT; SERPINA1) deficiency
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today